Related to this topic: Leaflets | Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Tick-borne Encephalitis Vaccination
Tick-borne Encephalitis (TBE) is caused by a flavivirus, the same family as yellow fever and japanese encephalitis.
It is usually spread by bites from ticks that are infected with the disease. Unpasteurised milk, especially from goats, is also implicated in spreading the disease.
The incubation time is 7-14 days. people initially develop a flu-like illness that lasts approximately 7 days. This may progress to encephalitis in 35-58% of cases1 with headache, fever, confusion, agitation and vomiting. Coma may follow. It is fatal in 1 in 30 cases.
The virus sub-type has a bearing on the course of the disease. The Eastern variant is more virulent, and leads to severe disease more often than the central one.
It is endemic to Russia, Eastern and Central Europe. The area spreads from the Rhine to the Urals, from Scandinavia to Italy and Greece. It is also endemic in Japan. Transmission mainly occurs in spring and summer, particularly in rural areas.
There has been an observed increase in the number of cases of TBE in recent years. This is thought to reflect a generally warmer climate, with an increase in numbers of ticks and rodents. In Europe 11,356 cases were reported in 1999. 83 % of those occurred in Russia.1 Symptomatic disease has been observed in all age groups.
There is no specific treatment for TBE once infected.
Prevention consists of:
- Individual prophylactic measures e.g. self-examination, extracting ticks after exposure and use of insect repellant
- Immunisation if travelling/spending time in endemic or high risk areas
There is only one licensed vaccine available in the UK.
FSME-Immun, available from MASTA. Tel. 0113 2387555.
This is not available on the NHS, and only on a named patient basis.
Austria has reported a sharp decline in cases in vaccinated areas and a vaccine efficacy rate of 95%.The main adverse effect reported is fever.
|
- Anaphylaxis:
- Should not be given to those who have had a confirmed anaphylactic reaction within 72 hours of a previous dose of the same vaccine.
- Also confirmed reaction to a constituent of the vaccine; TBE vaccine is produced in egg protein. Allergy testing should be performed with diluted vaccine.
- Other severe adverse reactions: This means an extensive area of redness and swelling affecting a large area of the arm or leg, accompanied by a fever of 39.5 degrees or higher, within 48 hours of the injection.
- The following DO NOT contraindicate vaccination:
- A personal or family history of asthma, allergy, hay fever or eczema
- Prematurity
- Stable neurological conditions e.g. cerebral palsy, Down's syndrome or epilepsy
- Contact with infectious disease
- Treatment with antibiotics or local corticosteroids
- Child is being breast fed or mother is pregnant
- Under weight
- Taking replacement corticosteroids
- Acute illness - Postpone immunisation until recovered. Minor infections, without fever or systemic upset are not reasons to postpone.
- Pregnancy - Inactive vaccine is probably safe. The risks to the fetus are likely to be negligible. Use only if there is a clearly indicated risk.
- Immunosuppression or HIV - Inactivated vaccines can be given, regardless of CD4 count. However these individuals may not be able to mount a full immune response.
Document references
- World Health Organisation; State of the art of new vaccines-research and development.
- Department of Health; The Green Book. Immunisation Against Infectious Disease 2006
- Immunizations - travel vaccinations, Clinical Knowledge Summaries (2007)
Internet and further reading
- NATHNAC; National Travel Health Network and Centre (NaTHNaC): provides advice on immunisations to health professionals only. Available weekdays 9-12 and 2-4.30pm. Phone 020 7380 9234.
- British National Formulary British Medical Association and Royal Pharmaceutical Society of Great Britain. London.
DocID: 427
Document Version: 2
DocRef: bgp25014
Last Updated: 21 Sep 2007
Review Date: 20 Sep 2008
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineInformation leaflets related to this topic (^ top of page)
Tick Borne Encephalitis ImmunisationMedical reference articles in PatientPlus related to this topic (^ top of page)
Ehrlichiosis
Tick Borne Viral EncephalitisOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
Medical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)

Want to search some more? Use the Google Search box below to search our site.

Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
